In the PROTECT VIII main study

Effective bleed protection with Jivi®1

Study Design Chart
  • Patients with 0 or 1 spontaneous bleed (defined as a joint or muscle bleed and no identified trauma) during weeks 1-10 of the main study.2
  • Patients with 2 or more spontaneous bleeds (defined as joint or muscle bleeds and no identified trauma) during weeks 1-10 of the main study.2
  • n=9/13 of these patients were on prior prophylaxis and had a mean number total ABR of 17.4 before entering the main study.1
     
  • ABR, annualized bleed rate.


In the PROTECT VIII long-term extension study

ABRs assessed with Jivi®4

While there were no predetermined efficacy objectives in the extension study, bleeding episodes were documented during the routine course of treatment

Study Design Chart
  • As of 1/31/2018 cutoff.4
  • Patients who switched dosing frequency at least once after the first week of the extension study were analyzed in a separate, variable-frequency group.5
     
  • ABR, annualized bleed rate.